POLBF - Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
(NewsDirect)
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)chief legal officer John McEvoy joins Proactive's Stephen Gunnionwith news that POLB 001's Immuno-modulator II has received thefully granted patent from the US Patent Office.
McEvoy explained the patent encompasses aclass of drugs for treating and preventing hypercytokinemia (cytokinestorms) in patients triggered by an immune response, applicable acrossmultiple disease indications.
Thegranted patent further solidifies Poolbeg Pharma's robustintellectual property portfolio for POLB 001, potentially increasingthe asset's value and making it more attractive to potentialpartners. McEvoy highlighted the company's ongoing efforts tostrengthen and expand their IP portfolio, noting existing patentscovering p38 MAP kinase inhibitors for influenza treatment andhypercytokinemia. Additional patents have been filed, particularlyfocusing on cancer immunotherapy applications of POLB 001.
Thecompany has also applied for patents concerning dosage regimens basedon results from their recent LPs trial, aiming to protect innovationsand maintain a competitive edge in the pharmaceutical market. Thisstrategic IP protection is crucial for safeguarding the company'sproducts and ensuring shareholder value, particularly as they seekpartnerships to further develop POLB 001.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.